There are currently 54 clinical trials in Waterbury, Connecticut looking for participants to engage in research studies. Trials are conducted at various facilities, including Smilow Cancer Hospital-Waterbury Care Center, Chase Medical Research, LLC, Pfizer Investigational Site and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Collection of Sputum and Labeling for Lung Cancer
NCT03457415
Recruiting
The primary objective of this study is to compare Assay results to diagnoses determined by currently accepted standards for lung cancer detection. This will be accomplished by analysis of sputum samples from three cohorts including healthy Participants, high risk Participants, and cancer patient Participants using the Assay as developed in accordance with findings of bioAffinity protocol BA-001 to confirm assay results. Adjustments will be made as necessary to finalize Assay design for clinical... Read More
Gender:
All
Ages:
21 years and above
Trial Updated:
07/25/2023
Locations: Waterbury Pulmonary Associates LLC, Waterbury, Connecticut
Conditions: Lung Cancer
Register for Updates
Comparing Two Methods to Follow Patients With Pancreatic Cysts
NCT04239573
Recruiting
The purpose of this study is to compare the two approaches for monitoring pancreatic cysts. The study doctors want to compare more frequent monitoring vs less frequent monitoring in order to learn which monitoring method leads to better outcome for patients with pancreatic cysts.
Gender:
All
Ages:
Between 50 years and 75 years
Trial Updated:
06/21/2023
Locations: Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut
Conditions: Pancreatic Carcinoma
Register for Updates
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
NCT04566328
Recruiting
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spread... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut
Conditions: Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
Register for Updates
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT03937635
Recruiting
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut
Conditions: Smoldering Plasma Cell Myeloma
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab
NCT05388474
Recruiting
The virological efficacy of ibalizumab has been clearly demonstrated in multiple clinical trials. This study will expand ibalizumab's clinical data set and allow a better understanding of the virologic response durability on ARV regimens with or without ibalizumab in a heterogeneous real-world patient population. Additional data on the efficacy and safety of ibalizumab and its impact on patient reported outcomes will be captured until study end. Primary Objective: To evaluate the long-term eff... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Waterbury Hospital, Waterbury, Connecticut
Conditions: HIV Infections, Multi-Antiviral Resistance
Register for Updates